A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia

A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia

Abstract Background Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-naïve and experienced persons living with HIV (PLWH). Case presentation A young man with recently diagnosed huma...

Full description

Bibliographic Details
Main Authors: Kanak Parmar, Poemlarp Mekraksakit, Kenneth Nugent, Jacob Nichols
Format: Article
Language:English
Published: BMC 2023-01-01
Series:AIDS Research and Therapy
Subjects:
Hyperbilirubinemia
Biktarvy
Bictegravir
Online Access:https://doi.org/10.1186/s12981-023-00501-7

Internet

https://doi.org/10.1186/s12981-023-00501-7

Similar Items